Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Biren Amin maintains an Overweight rating on Immunome (NASDAQ:IMNM) but lowers the price target from $27 to $23.
August 13, 2024 | 11:25 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on Immunome but lowers the price target from $27 to $23.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100